Larimar Stock Plummets: Anaphylaxis Events in Drug Study

Larimar's experimental drug for Friedreich's ataxia, nomlabofusp, showed positive biological results and improved clinical trends, but safety concerns over seven cases of anaphylaxis caused the stock to drop dramatically.